Global NDDS in Cancer Therapy Market by Type (Dendrimers, Liposomes, Micelles), Mode (Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, Targeted Drug Delivery Systems), Route of Administration, Application, End-User - Forecast 2024-2030- Product Image

Sale

Global NDDS in Cancer Therapy Market by Type (Dendrimers, Liposomes, Micelles), Mode (Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, Targeted Drug Delivery Systems), Route of Administration, Application, End-User - Forecast 2024-2030

Report
188 Pages
March 2024
Region: Global
360iResearch™
ID: 5888824

UP TO €841EUR$875USD£719GBP OFF until Dec 31^st 2024

The NDDS in Cancer Therapy Market size was estimated at USD 10.41 billion in 2023, USD 11.75 billion in 2024, and is expected to grow at a CAGR of 13.28% to reach USD 24.94 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the NDDS in Cancer Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the NDDS in Cancer Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the NDDS in Cancer Therapy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca, Boston Scientific Corporation, Cospheric LLC, Enable Injections, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Merit Medical Systems, MO-SCI Corporation, Novartis AG, Pacira BioSciences, Inc., Pfizer Inc., Samyang Holdings Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services, Inc.

Market Segmentation & Coverage

This research report categorizes the NDDS in Cancer Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Dendrimers
- Liposomes
- Micelles
- Nanoparticles
Mode
- Controlled Drug Delivery Systems
- Modulated Drug Delivery Systems
- Targeted Drug Delivery Systems
Route of Administration
- Injectable Drug Delivery Systems
- Oral Drug Delivery Systems
- Pulmonary Drug Delivery Systems
- Transdermal Drug Delivery Systems
Application
- Brain Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
End-User
- Ambulatory Surgical Centers
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the NDDS in Cancer Therapy Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the NDDS in Cancer Therapy Market?
What are the technology trends and regulatory frameworks in the NDDS in Cancer Therapy Market?
What is the market share of the leading vendors in the NDDS in Cancer Therapy Market?
Which modes and strategic moves are suitable for entering the NDDS in Cancer Therapy Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. NDDS in Cancer Therapy Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer across the globe
5.1.1.2. Increasing need of NDDS to imrove drug solubility and reduce toxicity
5.1.1.3. Accelerating investments for development of novel drug delivery systems for cancer
5.1.2. Restraints
5.1.2.1. Limited awareness and involvement of huge cost
5.1.3. Opportunities
5.1.3.1. Emerging government initiatives coupled with favorable reimbursement policies
5.1.3.2. Ongoing research activities for advanced anti-cancer nano drug delivery system
5.1.4. Challenges
5.1.4.1. Dearth of skilled and experienced medical professionals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization

6. NDDS in Cancer Therapy Market, by Type

6.1. Introduction
6.2. Dendrimers
6.3. Liposomes
6.4. Micelles
6.5. Nanoparticles

7. NDDS in Cancer Therapy Market, by Mode

7.1. Introduction
7.2. Controlled Drug Delivery Systems
7.3. Modulated Drug Delivery Systems
7.4. Targeted Drug Delivery Systems

8. NDDS in Cancer Therapy Market, by Route of Administration

8.1. Introduction
8.2. Injectable Drug Delivery Systems
8.3. Oral Drug Delivery Systems
8.4. Pulmonary Drug Delivery Systems
8.5. Transdermal Drug Delivery Systems

9. NDDS in Cancer Therapy Market, by Application

9.1. Introduction
9.2. Brain Cancer
9.3. Breast Cancer
9.4. Lung Cancer
9.5. Pancreatic Cancer

10. NDDS in Cancer Therapy Market, by End-User

10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Hospitals
10.4. Specialty Clinics

11. Americas NDDS in Cancer Therapy Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific NDDS in Cancer Therapy Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa NDDS in Cancer Therapy Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. AstraZeneca
15.1.3. Boston Scientific Corporation
15.1.4. Cospheric LLC
15.1.5. Enable Injections
15.1.6. GlaxoSmithKline PLC
15.1.7. Johnson & Johnson Services, Inc.
15.1.8. Merck & Co., Inc.
15.1.9. Merit Medical Systems
15.1.10. MO-SCI Corporation
15.1.11. Novartis AG
15.1.12. Pacira BioSciences, Inc.
15.1.13. Pfizer Inc.
15.1.14. Samyang Holdings Corporation
15.1.15. Sanofi S.A.
15.1.16. Teva Pharmaceutical Industries Ltd.
15.1.17. West Pharmaceutical Services, Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing

List of Figures

FIGURE 1. NDDS IN CANCER THERAPY MARKET RESEARCH PROCESS
FIGURE 2. NDDS IN CANCER THERAPY MARKET SIZE, 2022 VS 2030
FIGURE 3. NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. NDDS IN CANCER THERAPY MARKET DYNAMICS
FIGURE 7. NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 8. NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2022 VS 2030 (%)
FIGURE 10. NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
FIGURE 12. NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 14. NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 16. NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 20. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 26. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. NDDS IN CANCER THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. NDDS IN CANCER THERAPY MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 11. NDDS IN CANCER THERAPY MARKET SIZE, BY CONTROLLED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. NDDS IN CANCER THERAPY MARKET SIZE, BY MODULATED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 15. NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. NDDS IN CANCER THERAPY MARKET SIZE, BY ORAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. NDDS IN CANCER THERAPY MARKET SIZE, BY PULMONARY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. NDDS IN CANCER THERAPY MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 20. NDDS IN CANCER THERAPY MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. NDDS IN CANCER THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. NDDS IN CANCER THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. NDDS IN CANCER THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. NDDS IN CANCER THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. NDDS IN CANCER THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. NDDS IN CANCER THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 46. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 73. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 78. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 88. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 118. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 132. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 144. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 163. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 164. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 178. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 179. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 184. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 188. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 189. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 208. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 209. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 222. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 238. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2022
TABLE 239. NDDS IN CANCER THERAPY MARKET LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
AstraZeneca
Boston Scientific Corporation
Cospheric LLC
Enable Injections
GlaxoSmithKline PLC
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Merit Medical Systems
MO-SCI Corporation
Novartis AG
Pacira BioSciences, Inc.
Pfizer Inc.
Samyang Holdings Corporation
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
West Pharmaceutical Services, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	188
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 11.75 Billion
Forecasted Market Value ( USD ) by 2030	$ 24.94 Billion
Compound Annual Growth Rate	13.2%
Regions Covered	Global
No. of Companies Mentioned	17

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3242EUR$3,374USD£2,772GBP €3602EUR$3,749USD£3,080GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4107EUR$4,274USD£3,511GBP €4563EUR$4,749USD£3,901GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4971EUR$5,174USD£4,250GBP €5524EUR$5,749USD£4,723GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5836EUR$6,074USD£4,990GBP €6485EUR$6,749USD£5,544GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7566EUR$7,874USD£6,468GBP €8406EUR$8,749USD£7,187GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

NDDS in Cancer Therapy - Global Strategic Business Report

Global Cancer Biological Therapy Market by Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines), Route of Administration (Intramuscular, Intravenous, Subcutaneous), End-Users - Forecast 2024-2030

Global Neoantigen Targeted Therapies Market by Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer), Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens), Immunotherapy Type, Route of Administration - Forecast 2024-2030

CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product (Abecma, Breyanzi), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region, And Segment Forecasts, 2023-2030